GRI Bio, Inc.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory, fibrotic, and autoimmune diseases driven by dysregulated immune responses. The company has no approved products yet and is focused on advancing product candidates such as GRI-0621 and GRI-0803 through preclinical and clinical development toward eventual commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in preclinical and clinical development, including GRI-0621 and GRI-0803.
Discovery and development work aimed at immune-response targets for inflammatory and autoimmune disease.
Potential marketed products if candidates receive regulatory approval and are launched.
Customers
GRI Bio does not yet sell commercial products, so its near-term 'customers' are primarily clinical trial participants, investigators, CROs, and regulatory agencies involved in development. If approved, the eventual buyers would be physicians, hospitals, and third-party payors treating patients with inflammatory, fibrotic, and autoimmune disorders.
CROs, investigators, and trial sites that execute studies and generate data needed for regulatory advancement.
FDA and other regulators that review safety, efficacy, and manufacturing data before approval.
Potential future prescribers in immunology, pulmonology, hepatology, and related specialties.
Commercial insurers and government programs that would influence adoption and reimbursement after approval.
End users of any approved therapy for inflammatory, fibrotic, or autoimmune disorders.
Strategy
The company’s strategy is to advance GRI-0621, GRI-0803, and future candidates through clinical development, while building the data package needed for regulatory approval. It also expects to raise capital and may seek collaborations or partnerships to fund development and reduce the burden of late-stage trials and commercialization.
The company has no approved products, so value creation depends on generating human efficacy and safety data.
Management disclosed substantial doubt about going concern and expects continued operating losses.
Clinical-stage biotech must demonstrate quality, safety, and manufacturability before approval.
Geography
GRI Bio is headquartered in La Jolla, California and operates as a U.S.-based development-stage biotech company. The business is currently centered on U.S. research, clinical, regulatory, and financing activities, with future commercial geography dependent on where approvals are obtained and where partners or patients are located.
Risks
GRI Bio faces the core risks of a clinical-stage biotech: development failure, regulatory setbacks, and the need for repeated financing before any product revenue exists. Its business is also exposed to third-party dependence, competition from better-capitalized drug developers, cybersecurity risk, and healthcare reimbursement and compliance constraints if products are eventually approved.
- Clinical development failureImpact: CriticalLikelihood: High
GRI-0621, GRI-0803, and other candidates must still prove safety and efficacy in trials.
Exposure: Lead programs
- Going concern / financing riskImpact: CriticalLikelihood: High
The company expects continued losses and disclosed substantial doubt about its ability to continue as a going concern.
Exposure: Corporate liquidity
- Regulatory approval riskImpact: HighLikelihood: High
Drug candidates require IND clearance, clinical success, and marketing approval before commercialization.
Exposure: FDA and other regulators
- Competition from larger biopharma companiesImpact: HighLikelihood: High
Competitors may have greater capital, broader pipelines, and faster development capabilities.
Exposure: Target disease areas such as IPF and autoimmune disorders
- Cybersecurity and third-party operational riskImpact: MediumLikelihood: Medium
The company relies on CROs, clinical sites, and contractors that process sensitive data and run trials.
Exposure: Research data and clinical operations
Accounting
Judgemental itemsCRO and vendor invoices may lag service delivery, requiring estimates based on trial progress.
Impact: Can shift quarterly R&D expense and liabilities materially
Employee and consultant equity awards are a meaningful non-cash expense for a small biotech.
Impact: Affects operating loss and comparability across periods
The company has an operating lease for office space that creates right-of-use assets and lease liabilities.
Impact: Impacts balance sheet leverage and occupancy expense timing
Management’s liquidity assumptions are central to whether the company can continue operations.
Impact: Important for interpreting financing risk and disclosure quality
Similar listed companies
Publicly listed companies with a comparable business focus.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Palisade Bio, Inc
PALI · Biological Products, (No Diagnostic Substances)
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Q32 Bio Inc.
QTTB · Pharmaceutical Preparations
Last updated: 24/09/2026